重组人血小板生成素在脓毒性血小板减少症中的应用

Effect of Recombinant Human Thrombopoietin in the Treatment of Septic-related Thrombocytopenia

血小板减少在脓毒症患者中常见,且与死亡率相关。因此对血小板减少的脓毒症患者早期干预有一定的临床意义。重组人血小板生成素(recombinant human thrombopoietin,rh TPO)具有与内源性血小板生成素相同的作用,刺激骨髓巨核细胞生长和分化,并最终分裂为成熟的血小板释放入外周血。由于rh TPO具有良好的升血小板作用和耐受性,近年来也逐渐用于治疗严重脓毒症引起的血小板减少。rh TPO在治疗脓毒症相关的血小板减少症中具有确切的疗效和耐受性,为血小板减少症提供了一个行之有效的方法。

Thrombocytopenia is prevalent in patients with severe sepsis, and it is associated with mortalities. So it＇s clinicalsignificant to early intervene in the thrombocytopenia in patients with sepsis. Recombinant human thrombopoietin （rhTPO） functions as endogenous platelet hormone, stimulating the growth and differentiation of megakaryocytes in the marrow, and eventually splitting into mature peripheral blood platelets. In recent years rhTPO has been gradually used to treat plate!et reduction caused by severe sepsis, for its good tolerability and good effect in increasing the platelet counts.